Physician profile
Scott E Neumann
NPI 1114981461
$2,677.04
in general payments reported to CMS, 2019-2025
30 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $286 · 2021: $508 · 2022: $374 · 2023: $51.78 · 2024: $273 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $645.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $370.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $273.88 | 2019-2025 | Airsupra, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $265.32 | 2019-2022 | |
| Amgen INC. | $224.89 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $168.49 | 2021-2025 | |
| Exact Sciences Corporation | $124.82 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $123.16 | 2019-2025 | Shingrix |
| Amarin Pharma, INC. | $107.95 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $105.80 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $94.19 | 2021-2022 | |
| Medtronic, INC. | $90.98 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.70 | 2019-2022 | |
| Daiichi Sankyo INC. | $85.98 | 2019-2024 | Injectafer |
| Astellas Pharma US INC | $80.68 | 2024-2025 | Veozah |
| Dynavax Technologies Corporation | $59.92 | 2023-2024 | Heplisav-B |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $57.82 | 2019 | |
| Si-Bone, INC. | $57.13 | 2019 | |
| Esperion Therapeutics, INC. | $36.30 | 2021-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.98 | 2022 | |
| Allergan, INC. | $35.64 | 2019-2020 | |
| Abbott Laboratories | $33.32 | 2022 | |
| Medtronic USA, INC. | $27.46 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $24.59 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.13 | 2022 | |
| Adlon Therapeutics L.P. | $16.31 | 2021 | |
| Eisai INC. | $15.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.94 | 2021 | |
| Genentech USA, INC. | $14.75 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.58 | 2021 | |
| Lilly USA, LLC | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Neumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.